These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22229817)

  • 1. Influence of natural and synthetic histone deacetylase inhibitors on chromatin.
    Licciardi PV; Kwa FA; Ververis K; Di Costanzo N; Balcerczyk A; Tang ML; El-Osta A; Karagiannis TC
    Antioxid Redox Signal; 2012 Jul; 17(2):340-54. PubMed ID: 22229817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory effects of histone deacetylase inhibitors.
    Licciardi PV; Ververis K; Tang ML; El-Osta A; Karagiannis TC
    Curr Mol Med; 2013 May; 13(4):640-7. PubMed ID: 23061676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
    Ververis K; Hiong A; Karagiannis TC; Licciardi PV
    Biologics; 2013; 7():47-60. PubMed ID: 23459471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
    Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
    Gryder BE; Sodji QH; Oyelere AK
    Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New patented histone deacetylase inhibitors.
    Wang H; Dymock BW
    Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: biology and mechanism of action.
    Mehnert JM; Kelly WK
    Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
    Zagni C; Floresta G; Monciino G; Rescifina A
    Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
    Ververis K; Karagiannis TC
    Am J Transl Res; 2012; 4(1):24-43. PubMed ID: 22347520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin for the treatment of non-Hodgkin's lymphoma.
    Yazbeck VY; Grant S
    Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential non-oncological applications of histone deacetylase inhibitors.
    Ververis K; Karagiannis TC
    Am J Transl Res; 2011; 3(5):454-67. PubMed ID: 22046487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance to histone deacetylase inhibitors.
    Lee JH; Choy ML; Marks PA
    Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
    Feng W; Zhang B; Cai D; Zou X
    Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies in developing promising histone deacetylase inhibitors.
    Zhang L; Fang H; Xu W
    Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.